Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-332 in moderate to severe chronic spontaneous urticaria uncontrolled by second-generation H1 antihistamines
CTR20255229Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of soficitinib in chronic idiopathic urticaria (CIU), sponsored by InnoCare Pharma. Started Feb 2026; status: active.
02
Drugs
soficitinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20255229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255229.